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Objectives: Currently, the most commonly applied approach to treatment of resist-
ant hypertension (TRH) is adding on mineralocorticoid receptor antagonists (MRAs) 
such as spironolactone to existing medication therapy. Newer treatment alterna-
tives for treating resistant hypertension were developed, however comparative 
effectiveness of these add-on strategies and MRAs is not established. Our objective 
is to perform a network-meta analysis of add-on treatment alternatives for MRAs 
in TRHTN and thus establish comparative effectiveness in terms of SBP and DBP 
reduction. MethOds: Recent meta-analyses for renal denervation (RDN) and placebo 
effect were supplemented with a systematic search for MRAs in TRHTN. Newer renal 
denervation articles were identified using Pubmed searches. Search terms included 
Randomized control trials (RCT), TRH, MRAs. We Independently extracted data using 
a pre-defined data extraction form, including Cohrane study quality indicators and 
the GRADE criteria. Network meta-analysis techniques were used to compare the 
effects of add-on treatment alternatives for TRHTN, using spironolactone as a com-
mon comparator. Results: We identified 16 articles which met our inclusion criteria. 
The results show that lack of add-on medication therapy leads to markedly higher 
blood pressure measurements than spironolactone, office SBP 24 [95% CI 2; 48] DBP 
7.4 [-2.9; 18]. While add-on placebo medication results in significantly higher blood 
pressure than add-on spironolactone, SBP 19 [5.7; 32] DBP 8.3[2.3; 14], add-on spirono-
lactone’s blood pressure reducing effects equal those of add-on sham operations SBP 
0.58 [-28; 29] DBP 0.36 [-12; 13]. cOnclusiOns: Currently, no active, add-on treatment 
strategy for TRHTN seems more effective than spironolactone. In addition, being the 
only effective active treatment strategy, research into future medicinal alternatives 
in TRHTN should use spironolactone as an active comparison, and as an obligatory 
background drug when investigating the effectiveness of device-based alternatives. 
Furthermore, trials investigating device-based alternatives such as renal denervation 
should always include sham procedure as a comparator.
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Objectives: To compare the cost and effectiveness of aspirin with that of clopi-
dogrel in acute myocardial infarction(AMI) patients from data of Beijing medical 
insurance database MethOds: We randomly selected 10% of patients diagnosed 
as AMI the first time during January 2012- December 2012 and then followed their 
inpatient records and prescription records to September 2013 from Beijing medical 
insurance database. We divided these patients into 5 groups according to their drug 
utilization records during the observation period. 1239 patients were divided into 
5 groups according to the proportion of aspirin prescription by 100.0%, 60.1-99.9%, 
40.0-60.0%, 0-39.9% and 0(clopidogrel only). We compared the rate of recurrences, 
cost of anti-platelet drugs and rate of hemorrhage events in different drug utiliza-
tion groups. The Kruskal-Wallis test and Bartlett’s test were used in the analy-
sis. Results: 1239 patients were identified(age 65.69±15.51, male 73.69%), 63 (2.54%) 
patients used aspirin only, 761 (61.42%) patients used aspirin more(60-100%), 289 
(23.33%) patients used 40-60% aspirin, 116 (9.36%) patients used aspirin 0-40% and 
10 (0.83%) patients used clopidogrel only. The MI recurrence rates for patients of 
different prescription groups were significantly different(p< 0.01), patients with only 
aspirin utilization recurred less than that of patients with 60-100% aspirin and 
40-60% aspirin prescription, patients with 0-40% aspirin prescription recurred less 
than that of patients with 60-100% aspirin prescription. The cost of anti-platelet 
drugs for patients of different drug groups was significantly different(p< 0.01), The 
hemorrhage rate of patients with only aspirin prescription was higher than that of 
patients with two drugs. cOnclusiOns: A small proportion of AMI patients used 
only one drug for anti-platelet treatment, while most patients used both aspirin and 
clopidogrel. Patients who used aspirin only had lower cost of anti-platelet drugs, 
lower rate of recurrence and higher rate of hemorrhage events. Further studies 
on cost-effectiveness for aspirin and clopidogrel would provide moret evidence.
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Objectives: To evaluate the burden to patients and the healthcare system associ-
ated with a new cardiovascular event (CVEs) up to 3 years post-new CVE among 
high-risk hyperlipidemia patients. MethOds: Using the IMS LifeLink PharMetrics 
Plus commercial claims database, this retrospective cohort study included high CV 
risk hyperlipidemia patients with and without a new CVE between 01/01/2006 and 
06/30/2012. CVEs included primary inpatient claims for myocardial infarction (MI), 
unstable angina (UA), ischemic stroke (IS), transient ischemic attack, revascularization 
and heart failure. Patients were stratified into two CV risk cohorts: history of cardio-
vascular disease (CVD) [MI, UA, coronary artery bypass graft, percutaneous coronary 
intervention, IS] and coronary heart disease risk equivalent (CHD RE) [peripheral 
artery disease, abdominal aortic aneurysm, coronary artery disease, diabetes, dys-
lipidemia]. Propensity score matching was applied to compare the burden among 
patients with and without a new CVE, ranging from 1 month through 3 years post-CVE 
date. Results: Using the IMS LifeLink PharMetrics Plus commercial claims data-
base, this retrospective cohort study included high CV risk hyperlipidemia patients 
ducted during a review of the company’s submission (CS) to the National Institute for 
Health and Care Excellence (NICE) Single Technology Appraisal programme for the 
oral direct thrombin inhibitor, dabigatran. MethOds:: Randomised controlled trials 
(RCTs) for inclusion were identified using the CS for dabigatran (as part of Technology 
Appraisal [TA]327), and two similar submissions for rivaroxaban (TA261 and TA287). 
RCTs were assessed for comparability based on patient population, disease severity, 
and treatments received. A Bayesian MTC was conducted, and fixed and random 
effects models were explored. Odds ratio (OR) was chosen as the summary statistic for 
VTE recurrence and major bleed. Results: The network of 9 RCTs formed a “radiating 
star”. The fixed effects model had the lowest deviance information criterion (DIC) for 
VTE recurrence and major bleed and so was chosen as the best-fitting model. There 
was reasonable agreement between the number of unconstrained data points and 
the residual deviance for both outcomes. Results compared to dabigatran were (OR> 1 
favours dabigatran): VTE recurrence LMWH OR 0.96 (95% Credible Interval [95%CrI]: 
0.15–3.37), rivaroxaban OR 1.29 (95%CrI: 0.12–5.42), warfarin OR 1.87 (95%CrI: 0.31–6.45); 
major bleed LMWH OR 0.85 (95%CrI: 0.15–2.67), warfarin OR 0.74 (95%CrI: 0.15–2.15). 
No data were available on major bleed for rivaroxaban in people with active can-
cer. cOnclusiOns: There were no significant differences in the outcomes evaluated. 
However, the available evidence suggests that LMWH may have the lowest risk of VTE 
recurrence in the treatments assessed.
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Objectives: To assess the association between adherence to heart failure (HF) 
evidence-based treatment (i.e. β -blocker + angiotension-converting enzyme inhibi-
tor or angiotensin receptor blocker or hydralazine + isosorbide dinitrate), and 1) 
one-year all-cause hospitalization and 2) one-year all-cause mortality, among 
people newly diagnosed for HF. MethOds: We conducted two nested case-control 
studies using Quebec (Canada) medico-administrative data. We selected cases and 
controls in a cohort made of Quebec residents ≥ 18 years who had a first diagnosis 
of HF between 01/01/2000 and 12/31/2009 and who did not use HF evidence-based 
treatment before their diagnosis. Cases were those hospitalized or who died in 
the year after HF diagnosis. Each case was randomly matched to 4 to 10 controls 
using incidence density sampling. Adherence to HF evidence-based treatment 
was assessed using the proportion of days covered (PDC). Odds ratios (OR) were 
calculated using conditional multivariable logistic regressions. Results: Among 
the 125,622 individuals in the cohort, 70,483 (56.1%) were hospitalized and 19,915 
(15.9%) died during the first year after diagnosis. Only 7.5% of hospitalization cases, 
9.5% of their controls, 6.9% of death cases and 11.6% of their controls had a PDC 
≥ 80%. Compared to those with a PDC ≥ 80%, patients who had a PDC > 0% and 
< 80% (OR= 1.39 (95% CI= 1.33-1.46) or a PDC = 0% (OR= 1.53 (1.48-1.58) were more 
likely to be hospitalized within the first year after diagnosis. Similarly, compared 
to those with a PDC ≥ 80%, patients who had a PDC > 0% and < 80% (OR= 1.72 (95% 
CI= 1.59-1.86) or a PDC = 0% (OR= 2.26 (2.13-2.40) were more likely to die during the 
year after diagnosis. cOnclusiOns: Adherence to HF evidence-based treatment 
is suboptimal. A low adherence could increase the risk of hospitalization and have 
a detrimental effect on survival of HF patients.
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Objectives: The introduction of prothrombin time (INR) point-of-care devices 
permits patient self-testing of the INR values and subsequently, also self-adjust-
ment of the dosing regimen. The purpose of this systematic review was to evaluate 
recent findings regarding the effects of self-monitoring and self-management of 
anticoagulation therapy with vitamin K antagonists (coumarins) compared to the 
standard ambulatory care. MethOds: A comprehensive literature search using 
OVID MEDLINE (1946 – April 2015) and EMBASE (1974 – April 2015) databases was 
performed. Selection criteria were restricted to randomized controlled clinical tri-
als evaluating self-monitoring or self-management with standard care as control. 
Meta-analysis was performed in Review Manager Computer program (Version 
5.3.) using a fixed-effect model with the Mantel-Haenszel method to calculate 
the pooled risk ratios (RR) and their 95% confidence interval (CI) of the following 
clinical outcomes: thromboembolic events, major haemorrhage, and all-cause 
mortality. Potential heterogeneity was assessed with I2 statistics. Results: In 
addition to the 2010 Cochrane review (Self-monitoring and self-management of 
oral anticoagulation), 10 novel randomized trials were identified; in 3 of them 
self-monitoring was evaluated, while in the other 7 studies self-management 
was assessed. Until the April 2015, self-monitoring and self-management was 
evaluated in 10 (4313 participants) and 19 (5413 participants) randomized tri-
als, respectively. Self-management was associated with significant reductions in 
both thromboembolic events (RR= 0.48, 95%CI: 0.35–0.65, p< 0.001) and mortality 
(RR= 0.70, 95%CI: 0.49–0.99, p= 0.046), while no significant effect on major bleedings 
was found (RR= 1.03, 95%CI: 0.77–1.38). In contrast to the 2010 Cochrane review 
no significant benefit of self-monitoring could be confirmed: the RRs were 0.91 
(95%CI: 0.71–1.16), 0.91 (95%CI: 0.75–1.10), and 0.94 (95%CI: 0.75–1.17) for the throm-
boembolic events, major bleedings, and mortality, respectively. cOnclusiOns: 
Compared to the standard ambulatory care, patient self-management of the INR 
values shows beneficial effects on their anticoagulant therapy. Moreover, self-
management better improves the probability of the occurrence of thromboembolic 
events than self-monitoring.
